<DOC>
	<DOC>NCT01246752</DOC>
	<brief_summary>Hematopoietic stem cell transplantation in patients with newly diagnosed AML ≤60 years of age in intermediate risk, after first complete response in comparison to standard consolidation chemotherapy</brief_summary>
	<brief_title>Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) &lt;= 60y. After First CR</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>AML in first remission cytological standard risk, i.e. karyotype not listed under exclusion criteria Identification of HLAidentical sibling or HLAcompatible related or unrelated donor (9/10 HLAalleles matched, high resolution typing for HLAA, B, Cw, DRB1 and DQB1) age: 18 60 years medically fit for allogeneic stem cell transplantation CR / CRi after induction therapy corebinding factor leukemia (t(8;21), inv16) acute promyelocytic leukemia (t(15;17) complex aberrant karyotype karyotypes: 7; 5; del5q; t(3;3); t(6;11), t(6;9), 11q aberrations, trisomy 8 ± one single additional aberration pregnancy / nursing noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>AML, Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>HSCT</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Tx</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>